Myriad Genetics appointed Vishal Sikri as executive vice president, commercial, effective September 16, 2026, replacing Brian Donnelly, who is leaving on September 21. Donnelly will remain a non-executive employee through that date to support the transition, while the company reaffirms its full-year 2026 financial guidance.
Key Highlights
- Vishal Sikri moved from senior vice president, product, to executive vice president, commercial, effective September 16, 2026.
- Brian Donnelly will leave Myriad Genetics on September 21, 2026, after serving as chief commercial officer since May 2025.
- Myriad Genetics reaffirmed its full-year 2026 financial guidance.
Myriad Genetics Inc. (NASDAQ: MYGN) appointed Vishal Sikri as executive vice president, commercial, effective September 16, 2026.
Sikri Takes Commercial Leadership Sikri previously served as
Myriad Genetics’ senior vice president, product. Donnelly is expected to remain with Myriad Genetics as a non-executive employee through September 21, 2026, to assist with the handover of his responsibilities. He had served as chief commercial officer since May 2025.
Full-Year 2026 Guidance Reaffirmed Myriad Genetics
reaffirmed its financial guidance for full-year 2026. Sikri said he was energized to lead the commercial organization and advance Myriad Genetics’ mission.
FAQs
Q: Who is Myriad Genetics’ new executive vice president, commercial?
A: Vishal Sikri became Myriad Genetics’ executive vice president, commercial, effective September 16, 2026. He previously served as the company’s senior vice president, product.
Q: When is Brian Donnelly leaving Myriad Genetics?
A: Brian Donnelly is expected to depart Myriad Genetics on September 21, 2026. He remains a non-executive employee through that date to support the transition.
Q: Did Myriad Genetics change its 2026 financial guidance?
A: Myriad Genetics reaffirmed its financial guidance for full-year 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.